Products - Diabetes | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 75 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 September 2024
Diabetic retinopathy: management and monitoring (NG242)
Product type:
Guidance
Programme:
NICE guideline
Published:
13 August 2024
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 May 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2024
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 December 2023
Ranibizumab for treating diabetic macular oedema (TA274)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2023
Published:
27 February 2013
Tirzepatide for treating type 2 diabetes (TA924)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 October 2023
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
11 May 2023
Published:
1 August 2015
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 March 2023
Neuropad for detecting preclinical diabetic peripheral neuropathy (MTG38)
Product type:
Guidance
Programme:
Medical technologies guidance
Last updated:
21 September 2022
Published:
10 September 2018
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 September 2022
Brolucizumab for treating diabetic macular oedema (TA820)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2022
Type 1 diabetes in adults: diagnosis and management (NG17)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
17 August 2022
Published:
26 August 2015
Faricimab for treating diabetic macular oedema (TA799)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Type 2 diabetes in adults: management (NG28)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
29 June 2022
Published:
2 December 2015
3C Patch for treating diabetic foot ulcers (MTG66)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
7 March 2022
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
16 December 2020
Published:
25 February 2015
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 February 2020
Diabetic foot problems: prevention and management (NG19)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
11 October 2019
Published:
26 August 2015
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 March 2019
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)
Product type:
Guidance
Programme:
Medical technologies guidance
Last updated:
25 March 2019
Published:
25 March 2014
Type 2 diabetes: prevention in people at high risk (PH38)
Product type:
Guidance
Programme:
Public health guideline
Last updated:
15 September 2017
Published:
12 July 2012
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
23 November 2016
Published:
26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 May 2016
Aflibercept for treating diabetic macular oedema (TA346)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (IPG518)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 March 2015
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2015
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)
Product type:
Guidance
Programme:
Medical technologies guidance
Last updated:
1 March 2015
Published:
31 December 2014
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2014
Type 2 diabetes prevention: population and community-level interventions (PH35)
Product type:
Guidance
Programme:
Public health guideline
Published:
10 May 2011
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 September 2008
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2008
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (IPG257)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 April 2008
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
13 December 2022
d-Nav insulin management app for type 2 diabetes (MIB285)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
8 February 2022
AI technologies for detecting diabetic retinopathy (MIB265)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
6 July 2021
Dexcom G6 for real-time continuous glucose monitoring (MIB233)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
3 November 2020
t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
22 September 2020
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
24 April 2018
FreeStyle Libre for glucose monitoring (MIB110)
Product type:
Advice
Programme:
Medtech innovation briefing
Last updated:
29 September 2017
Published:
3 July 2017
Aptiva for painful diabetic neuropathy (MIB119)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
13 September 2017
MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
12 February 2016
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Product type:
Advice
Programme:
Evidence summary
Published:
2 December 2015
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Product type:
Advice
Programme:
Evidence summary
Published:
2 December 2015
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Product type:
Advice
Programme:
Evidence summary
Published:
3 July 2015
Type 2 diabetes: insulin degludec (ESNM25)
Product type:
Advice
Programme:
Evidence summary
Published:
10 September 2013
Type 1 diabetes in adults (QS208)
Product type:
Quality standard
Published:
2 March 2023
Type 2 diabetes in adults (QS209)
Product type:
Quality standard
Published:
2 March 2023
Diabetes in pregnancy (QS109)
Product type:
Quality standard
Last updated:
10 January 2023
Published:
19 January 2016
Diabetes in children and young people (QS125)
Product type:
Quality standard
Last updated:
31 March 2022
Published:
14 July 2016
Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)
Product type:
Quality standard
Published:
11 May 2018
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 July 2025
Type 2 diabetes in adults: management (medicines update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
30 July 2025
Diabetic retinopathy - ruboxistaurin [ID382]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Semaglutide for treating type 2 diabetes [ID1450]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes [ID1451]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sotagliflozin for treating type 2 diabetes [ID1657]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Insulin icodec for treating type 2 diabetes [ID6175]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aflibercept for untreated diabetic macular oedema [TSID10621]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cardiometabolic disease prevention and treatment guidelines
Status:
In development
Programme:
NICE Hub
Expected publication date:
TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
AI in retinal scanning MT524 (MIB265)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Insulin efsitora alfa for treating type 2 diabetes in people on daily insulin injections [ID6499]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [TSID12131]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC